Overview

Increased understanding of the impact of various risk factors on future osteo-porotic fracture risk and the role of BMD testing has created a gap in what research is beginning to show and what is understood in the community. Furthermore, no treatment strategy is best for all patients. In addition to appropriate risk stratification, a thorough understanding of the available management strategies is necessary to optimize and individualize osteoporosis therapy in postmenopausal women. OB/GYNs care for a large portion of these women at risk, and education is needed to close this educational gap and improve patient outcomes.

This CME program will apprise OB/GYNs of recent advances in the understanding of absolute fracture risk and the management of postmenopausal women at varying risk for osteoporotic fracture. Physician participants will benefit from a higher level of competency, in both fracture risk assessment and available management strategies, and will be able to individualize osteoporosis therapy in both primary and secondary prevention.

Faculty

	Faculty	Faculty Disclosures
	Andrea Singer, MD (Chairperson) Associate Professor Department of Obstetrics and Gynecology and Department of Medicine Georgetown University Medical Center Washington, DC	Andrea Singer, MD Speaker: Proctor & Gamble, Sanofi Aventis Consultant: Proctor & Gamble
	Neil Binkley, MD Associate Director, Institute on Aging Associate Professor University of Wisconsin Department of Medicine Madison, WI	Neil Binkley, MD Speaker: Novartis, Merck, Roche, Proctor & Gamble, Glaxo Smith Kline Research: Novartis, Merck, Roche, Aventis, Glaxo Smith Kline, Deltanoid, Macroflux Consultant: Novartis, Merck, Eli Lilly, Sciele
	Ellen Hirschman Miller, MD Clinical Associate Professor of Medicine Albert Einstein College of Medicine Vice President of Academic Affairs Southside Hospital | Bay Shore, NY	Ellen Hirschman Miller, MD Speaker: Glaxo Smith Kine, Roche, Merck, Novartis

Target Audience

This program was developed for OB/GYN Clinicians attending the 2008 Annual ACOG Meeting.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Define "Absolute Fracture Risk"
• Outline the criteria for initiating pharmacotherapy for primary prevention in postmenopausal osteoporosis
• Review the pharmacologic interventions available in the treatment of postmenopausal osteoporosis and the effect of therapeutic agents on bone density and fracture risk

CME Accreditation

The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.25 AMA PRA Category I credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

The following staff members of the Potomac Center for Medical Education involved in the development of content for this activity disclosed that they have no relevant financial relationships: Carole Drexel, PhD, Medical Science Liaison, Kathy Merlo, Medical Writer, Donna Fucello, Vice President, Clinical Education Division & Accreditation Services, Blair St. Amand, Editor, Dana Simpler, MD, external medical reviewer.

FDA Disclosure

The contents of some CME/CE activities may contain discussions of non-approved or off label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Supported by

This program is supported by an educational grant from

By clicking this button you are agreeing that you have read and understood the CME Statements above